Novel Uracil-Based Inhibitors of Acetylcholinesterase with Potency for Treating Memory Impairment in an Animal Model of Alzheimer's Disease

• Published in: Molecules (Basel, Switzerland) Switzerland), 2022-11, Vol.27 (22), p.7855
• Main Authors: Semenov, Vyacheslav E, Zueva, Irina V, Lushchekina, Sofya V, Suleimanov, Eduard G, Gubaidullina, Liliya M, Shulaeva, Marina M, Lenina, Oksana A, Petrov, Konstantin A
• Format: Article
• Language: English
• Subjects: 6-methyluracil; Acetylcholinesterase; Acids; Alzheimer Disease - drug therapy; Alzheimer's disease; Ammonium; Analysis; Animal models; Animals; Benzene; Benzoates; Benzoic acid; Chains; Disease Models, Animal; Esters; Genetic engineering; Hydrocarbons; Impairment; inhibitors; Memory; Memory Disorders - drug therapy; peripheral anionic site; Plaque, Amyloid; Plaques; Pyrimidines; Uracil; Uracil - pharmacology; Uracil - therapeutic use; β-Amyloid
• ISSN: 1420-3049; 1420-3049
• DOI: 10.3390/molecules27227855

Novel derivatives based on 6-methyluracil and condensed uracil, 2,4-quinazoline-2,4-dione, were synthesized with terminal - and -benzoate moieties in polymethylene chains at the N atoms of the pyrimidine ring. In the synthesized compounds, the polymethylene chains were varied from having tris- to hexamethylene chains and quaternary ammonium groups; varying substituents (ester, salt, acid) at benzene ring were introduced into the chains and benzoate moieties. In vivo biological experiments demonstrated the potency of these compounds in decreasing the number of β-amyloid plaques and their suitability for the treatment of memory impairment in a transgenic model of Alzheimer's disease.